FPA-150 is under clinical development by Amgen and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect FPA-150’s likelihood of approval (LoA) and phase transition for Endometrial Cancer took place on 12 Jan 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 12 Jan 2022 decreased FPA-150’s LoA and PTSR for Metastatic Breast Cancer, and decreased LoA and PTSR for Triple-Negative Breast Cancer (TNBC).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their FPA-150 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

FPA-150 overview

FPA-150 is under development for the treatment of advanced or metastatic breast, triple negative breast cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer and endometrial cancer. The drug candidate is a monoclonal antibody acts by targeting B7-H4.

It was also under development for the treatment of bladder cancer.

Amgen overview

Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.

Quick View FPA-150 LOA Data

Report Segments
  • Innovator
Drug Name
  • FPA-150
Administration Pathway
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Amgen
  • Originator: Five Prime Therapeutics
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.